Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries along with its subsidiary (Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics Inc., to resolve the pending patent litigation involving Ampyra (dalfampridine) extended-release tablets in US. The pending patent litigation was filed by Acorda Therapeutics in the US District Court for the District of Delaware in response to Sun Pharma’s submission of an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (USFDA), seeking marketing approval for a generic version of Ampyra.

As a result of the settlement agreement, Sun Pharma will be permitted to market a generic version of Ampyra in the United States at a specified date in 2027, or potentially earlier under certain circumstances. As per IMS MAT July 2015, Ampyra recorded annual sales of approximately $325 million in the US.

Sun Pharmaceutical Industries is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.